The Pandemic's Effect on Diagnosis and Treatment of Rectal Cancer
CovidRC
An Analysis of Covid-19 Effect on Patients With Colorectal Cancer - Follow-up Regarding Tumour Stage, Neoadjuvant Treatment, Delay and Long-term Survival
1 other identifier
observational
8,000
1 country
1
Brief Summary
Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown. The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 15, 2022
CompletedFirst Submitted
Initial submission to the registry
April 13, 2022
CompletedFirst Posted
Study publicly available on registry
April 14, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedDecember 8, 2023
December 1, 2023
2.9 years
April 13, 2022
December 7, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Yearly incidence of rectal cancer
The number of patients diagnosed yearly 2019, 2020, 2021 and 2022
2019-2022
Secondary Outcomes (4)
Symptoms at diagnosis
6 months prior diagnosis
Patient's delay
12 months prior diagnosis
Doctor's delay
12 months prior diagnosis
Treatment changes
Diagnosis and 12 months following
Study Arms (1)
Patients diagnosed before, during or after the pandemic
Patients with rectal cancer
Interventions
We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic
Eligibility Criteria
All patients that are diagnosed with rectal cancer and identified in the Swedish ColoRectal Cancer Registry will be included. They will be contacted by phone and mail regarding a questionnaire.
You may qualify if:
- Rectal cancer diagnosis 2019-2022
You may not qualify if:
- No rectal cancer diagnosis 2019-2022
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dept. of Surgery, Sahlgrenska University Hospital/Ostra
Gothenburg, SE 416 85, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 13, 2022
First Posted
April 14, 2022
Study Start
February 15, 2022
Primary Completion
December 31, 2024
Study Completion
December 31, 2025
Last Updated
December 8, 2023
Record last verified: 2023-12